

Unaudited Consolidated Income Statement

For the six months ended 31 December 2005

| | Note | Six months ended 31 December | |
|---|-------|------------------------------|----------------------------------|
| | | 2005 RMB'000 | 2004 (As restated) RMB'000 |
| Turnover | 3 | 1,286,230 | 1,052,632 |
| Cost of sales | | (422,525) | (358,584) |
| Gross profit | | 863,705 | 694,048 |
| Gain arising from changes in fair value less estimated point-of-sale costs of biological assets | | 18,831 | 150,740 |
| Other revenues | | 71,822 | 19,253 |
| Selling and distribution expenses | | (128,283) | (111,553) |
| General and administrative expenses | | (77,176) | (63,879) |
| Research expenses | | (23,902) | (27,005) |
| Other operating expenses | | (46,426) | (33,908) |
| Profit from operations | | 678,571 | 627,696 |
| Finance costs | 5 (a) | (83,717) | (4,634) |
| Share of net profit of associates | | 20,401 | 23,157 |
| Deemed loss on diluting the interest in associates | 10 | (33,881) | — |
| Profit from ordinary activities before income tax | 5 | 581,374 | 646,219 |
| Income tax | 6 | (25) | — |
| Profit from ordinary activities after income tax | | 581,349 | 646,219 |
| Profit attributable to: | | | |
| Shareholders of the Company | | 581,326 | 647,068 |
| Minority interests | | 23 | (849) |
| | | 581,349 | 646,219 |
| Dividends | 7 | 262,364 | 198,494 |
| Earnings per share for profit attributable to the shareholders of the Company during the period | | | |
| — Basic | 8(a) | RMB0.25 | RMB0.28 |
| — Diluted | 8(b) | RMB0.24 | RMB0.27 |